Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Cancer
Interventions: Personality Feedback Self-Management Intervention; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Obesity & Overweight, Diabetes (DM)
Interventions: Glucagon-Like Peptide-1 Agonist (GLP-1); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, carboplatin, epirubicin hydrochloride, microarray analysis, polymorphism analysis, pharmacological study; Drug · Genetic · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years to 120 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lymphoma
Interventions: aldesleukin, filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, teniposide, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma, Follicular
Interventions: Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 15 more

Conditions: Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions: Free Eye Screenings, Enhanced Intervention, Usual Care; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 906 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type II, Periodontitis
Interventions: Chlorhexidine gluconate oral rinse, Scaling & Root Planing, Soft Picks; Drug · Procedure · Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 25 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 429
States / cities: Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more

Conditions: Abortion Early
Interventions: Transabdominal sonography, Transvaginal sonography; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 634 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Morristown, New Jersey • New York, New York

Conditions: Alzheimer Disease
Interventions: Group-based Cognitive Behavioral Therapy (CBT), Phone-based Cognitive Behavioral Therapy (CBT); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoma
Interventions: Duvelisib, Rituximab, R-CHOP, Prednisone; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Intubation, Endotracheal
Interventions: Ambu Laryngeal Mask, Aintree Exchange Catheter, Laryngeal Mask Airway; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: Tailored Telephone Counseling; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Suicide, Attempted, Suicide Threat
Interventions: WET-SP, TAU; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Aortic Valve Disease
Interventions: VIV TAVR with BVF using TCEP; Device
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Dexmedetomidine, Congenital Heart Disease
Interventions: Dexmedetomidine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 6 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anesthesia, Surgery
Interventions: I-Gel Laryngeal Mask Airway, Ambu Auragain Laryngeal Mask Airway; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Colorectal Cancer
Interventions: Colonoscopy; Procedure
Lead sponsor: Oslo University Hospital; Other
Eligibility: 55 Years to 64 Years
Enrollment: 95,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2036
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Post-operative Vomiting
Interventions: Apple Juice, Water; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 2 Years to 18 Years
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Traumatic Brain Injury (TBI) Patients, Severe Traumatic Brain Injury
Interventions: SeeMe Multimodal Auditory Command Protocol; Diagnostic Test
Lead sponsor: Stony Brook University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Lymphoma, B-Cell
Interventions: cyclophosphamide, etoposide, rituximab, cytarabine, doxorubicin, tositumomab; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Traumatic Brain Injury, Closed Head Injury, Cognitive Dysfunction
Interventions: Real LED Intervention, Sham LED Intervention; Device
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Foot Ulcer
Interventions: Personalized Behavioral Intervention, Current Best Practice; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Search by objective public record fields.

Personality and Cancer Care Study

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

Impact of Periodontal Therapy on Patients With Diabetes

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Transabdominal and Transvaginal Sonography in Medical Abortion

CBT for African Americans With Cognitive Impairment

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Ambu® Laryngeal Mask as an Intubation Conduit

CHOICES: Understanding Clinical Trials as a Treatment Option

Written Exposure Therapy for Suicide Prevention

Quantification of Debris Captured Using TCEP During VIV TAVR With BVF

Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease

Comparison of Ambu Auragain and I-Gel Supraglottic Airways in Adult Patients at an Ambulatory Surgery Center

The Northern-European Initiative on Colorectal Cancer

Does First Oral Intake After Emergence Predict the Incidence of Post-operative Vomiting in Children?

SeeMe: Using Automated Facial Tracking to Detect Voluntary Behavior in Brain Injury

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Photobiomodulation to Improve Cognition in TBI, With fMRI

Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)